API Roflumilast CAS 162401-32-3 Pharmaceutical Raw Materials

API Roflumilast CAS 162401-32-3 pharmaceutical raw materials

Roflumilast
Phosphodiesterase 4 (PDE - 4) inhibitor is a new COPD drug. It is used to treat symptoms of cough and mucus in bronchitis patients with severe COPD. Flurost is not intended for the treatment of COPD patients with concurrent primary emphysema.
Alias: roflurodivision /ROFLUMILAST/3- (cyclopromethoxy) -N- (3,5- two chloro -4- pyridyl) -4- (two fluoromethoxy) benzamide; 3- (cyclopropyl methoxy) -N- (3,5- two chloropridine -4-) -4- (two fluoromethoxy) benzamide
English Name: Roflumilast
CAS 162401-32-3
Molecular formula: C17H14Cl2F2N2O3
Molecular weight: 403.2075
Melting point: 158 degrees centigrade
Relative density: 1.471g/cm3
3 action mechanism
Flurost is a long-acting inhibitor of type 4 phosphodiesterase (PDE-4), which has anti-inflammatory effects. Phosphodiesterase is a group of enzymes that contain at least 11 subtypes of enzymes, which catalyze the decomposition of messenger molecules cyclic adenylate and / or cyclic guanylate. Phosphodiesterase -4 is a major cyclic adenylate metabolic enzyme in inflammation and immune cells, and phosphodiesterase -4 inhibitors have extensive anti-inflammatory activities, including inhibiting the release of inflammatory mediators and inhibiting the activation of immune cells. In addition, phosphodiesterase -4 inhibitors have been shown to have therapeutic effects in animal airway inflammation models.
Roflurox selectively inhibits PDE4 and blocks the transmission of inflammatory response signals, and then inhibits the damage to lung tissues such as COPD and asthma: cyclic nucleotide cAMP and cGMP are important second messengers in the cells, and the biological responses of various extracellular signals including hormones, autologous active substances and neurotransmitters. It plays an important role. Phosphodiesterase (PDE) has the function of hydrolyzing cAMP or cGMP in cells, making it a key enzyme for the loss of inactive single nucleotides, and is the only way to hydrolyze cAMP and cGMP. The PDE family has 11 different members, namely PDE1~ PDE11, which are expressed differently in different tissues and cells. They are different in structure, biochemistry and pharmacology. PDE4 is the main regulator of cAMP metabolism, the main PDE isozyme of inflammation and immune cells, and also the main PDE isozyme distributed in the lungs. It is the largest group in the PDE family, with 4 subtypes (PDE4A, B, C, D). Each subtype is derived from 1 different genes and contains many variants. The various PDF4 molecules have 3 highly homologous regions: the hydrolytic catalytic site is located at the center to the C end, and the two upstream conserved regions (up-stream conserved regions, UCRl and UCR2). PDE4 is associated with the cAMP hydrolysis of a variety of inflammatory cells. Because cAMP can cause bronchial smooth muscle relaxation and pulmonary inflammatory response, inhibition of PDE4 can reduce the release of inflammatory mediators, and then inhibit the injury of respiratory diseases such as COPD and asthma to the lung tissue.


  API Roflumilast CAS 162401-32-3 pharmaceutical raw materials

Roflumilast
Phosphodiesterase 4 (PDE - 4) inhibitor is a new COPD drug. It is used to treat symptoms of cough and mucus in bronchitis patients with severe COPD. Flurost is not intended for the treatment of COPD patients with concurrent primary emphysema.
Alias: roflurodivision /ROFLUMILAST/3- (cyclopromethoxy) -N- (3,5- two chloro -4- pyridyl) -4- (two fluoromethoxy) benzamide; 3- (cyclopropyl methoxy) -N- (3,5- two chloropridine -4-) -4- (two fluoromethoxy) benzamide
English Name: Roflumilast
CAS 162401-32-3
Molecular formula: C17H14Cl2F2N2O3
Molecular weight: 403.2075
Melting point: 158 degrees centigrade
Relative density: 1.471g/cm3
3 action mechanism
Flurost is a long-acting inhibitor of type 4 phosphodiesterase (PDE-4), which has anti-inflammatory effects. Phosphodiesterase is a group of enzymes that contain at least 11 subtypes of enzymes, which catalyze the decomposition of messenger molecules cyclic adenylate and / or cyclic guanylate. Phosphodiesterase -4 is a major cyclic adenylate metabolic enzyme in inflammation and immune cells, and phosphodiesterase -4 inhibitors have extensive anti-inflammatory activities, including inhibiting the release of inflammatory mediators and inhibiting the activation of immune cells. In addition, phosphodiesterase -4 inhibitors have been shown to have therapeutic effects in animal airway inflammation models.
Roflurox selectively inhibits PDE4 and blocks the transmission of inflammatory response signals, and then inhibits the damage to lung tissues such as COPD and asthma: cyclic nucleotide cAMP and cGMP are important second messengers in the cells, and the biological responses of various extracellular signals including hormones, autologous active substances and neurotransmitters. It plays an important role. Phosphodiesterase (PDE) has the function of hydrolyzing cAMP or cGMP in cells, making it a key enzyme for the loss of inactive single nucleotides, and is the only way to hydrolyze cAMP and cGMP. The PDE family has 11 different members, namely PDE1~ PDE11, which are expressed differently in different tissues and cells. They are different in structure, biochemistry and pharmacology. PDE4 is the main regulator of cAMP metabolism, the main PDE isozyme of inflammation and immune cells, and also the main PDE isozyme distributed in the lungs. It is the largest group in the PDE family, with 4 subtypes (PDE4A, B, C, D). Each subtype is derived from 1 different genes and contains many variants. The various PDF4 molecules have 3 highly homologous regions: the hydrolytic catalytic site is located at the center to the C end, and the two upstream conserved regions (up-stream conserved regions, UCRl and UCR2). PDE4 is associated with the cAMP hydrolysis of a variety of inflammatory cells. Because cAMP can cause bronchial smooth muscle relaxation and pulmonary inflammatory response, inhibition of PDE4 can reduce the release of inflammatory mediators, and then inhibit the injury of respiratory diseases such as COPD and asthma to the lung tissue.


 

Biological Products

Chondroitin Sulfate,Pharmaceutical Chemical,Biological Products

Pharmaceutical Intermediate Co., Ltd. , http://www.nspharmaceutical.com